We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-10.55%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$353M
AUM Growth
-$40.7M
Cap. Flow
+$13.6M
Cap. Flow %
3.86%
Top 10 Hldgs %
52.84%
Holding
90
New
8
Increased
24
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$4.3M
2
STOK icon
Stoke Therapeutics
STOK
+$2.54M
3
DNLI icon
Denali Therapeutics
DNLI
+$2.45M
4
INGN icon
Inogen
INGN
+$2.35M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$2.12M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$3.28M
2
AXGN icon
Axogen
AXGN
+$3M
3
ATRC icon
AtriCure
ATRC
+$1.83M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$877K
5
ALKS icon
Alkermes
ALKS
+$864K

Sector Composition

Rank Sector Weight
1 Healthcare 85.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
26
Inogen
INGN
$176M
$3.27M 0.93%
458,065
+249,275
+119% +$2.35M
PODD icon
27
Insulet
PODD
$9.66B
$3.13M 0.89%
11,900
-500
-4% -$135K
ALKS icon
28
Alkermes
ALKS
$8.11B
$3.11M 0.88%
94,200
-26,500
-22% -$864K
KURA icon
29
Kura Oncology
KURA
$824M
$3.06M 0.87%
463,368
+15,000
+3% +$117K
STOK icon
30
Stoke Therapeutics
STOK
$2.06B
$2.95M 0.84%
443,998
+272,901
+160% +$2.54M
IMVT icon
31
Immunovant
IMVT
$8.21B
$2.91M 0.82%
169,996
+62,000
+57% +$1.3M
BCAX
32
Bicara Therapeutics
BCAX
$1.81B
$2.76M 0.78%
212,001
+106,501
+101% +$1.41M
ARAY icon
33
Accuray
ARAY
$33.8M
$2.19M 0.62%
1,222,358
– –
TSVT
34
DELISTED
2seventy bio
TSVT
$2.12M 0.6%
429,252
– –
PRQR icon
35
ProQR Therapeutics
PRQR
$268M
$2.08M 0.59%
1,567,561
– –
CMPS
36
Compass Pathways
CMPS
$1.83B
$2.03M 0.58%
711,046
+467,836
+192% +$1.8M
ALLO icon
37
Allogene Therapeutics
ALLO
$680M
$2.01M 0.57%
1,380,118
+140,000
+11% +$264K
TELA icon
38
TELA Bio
TELA
$38.5M
$1.76M 0.5%
1,441,029
– –
ALGN icon
39
Align Technology
ALGN
$12B
$1.75M 0.5%
11,000
+5,500
+100% +$1.08M
DNLI icon
40
Denali Therapeutics
DNLI
$3.92B
$1.74M 0.49%
+127,900
New +$2.45M
ATXS
41
DELISTED
Astria Therapeutics
ATXS
$1.68M 0.48%
314,775
+15,000
+5% +$105K
VKTX icon
42
Viking Therapeutics
VKTX
$3.88B
$1.56M 0.44%
64,516
– –
RGLS
43
DELISTED
Regulus Therapeutics
RGLS
$1.48M 0.42%
847,176
-28,024
-3% -$37K
BWAY
44
Brainsway
BWAY
$628M
$1.48M 0.42%
313,066
-73,350
-19% -$372K
ORIC icon
45
Oric Pharmaceuticals
ORIC
$1.34B
$1.35M 0.38%
+242,000
New +$2.12M
KROS icon
46
Keros Therapeutics
KROS
$211M
$1.33M 0.38%
130,316
– –
LXEO icon
47
Lexeo Therapeutics
LXEO
$357M
$1.31M 0.37%
378,083
-15,000
-4% -$66.5K
ITOS
48
DELISTED
iTeos Therapeutics
ITOS
$1.27M 0.36%
213,347
+25,000
+13% +$184K
PVLA
49
Palvella Therapeutics
PVLA
$2.23B
$1.21M 0.34%
43,348
-28,104
-39% -$542K
SPRY icon
50
ARS Pharmaceuticals
SPRY
$551M
$1.2M 0.34%
95,290
+6,500
+7% +$78.2K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, DAFNA Capital Management held 90 positions worth $353M, down 10% from $393M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $13.6M of net new capital in Q1 2025, opening 8 new positions and adding to 24 existing holdings. Its largest new stake was Denali Therapeutics: 127,900 shares worth $1.74M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $3.28M trimmed.

  • DAFNA Capital Management's largest Q1 2025 buy was Denali Therapeutics: 127,900 shares worth $1.74M.
  • DAFNA Capital Management added most to Arcus Biosciences in Q1 2025, an estimated $4.3M increase.
  • DAFNA Capital Management's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $3.28M.
  • DAFNA Capital Management fully exited Centessa Pharmaceuticals in Q1 2025, selling an estimated $795K.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $353M portfolio in Q1 2025.
  • DAFNA Capital Management opened 8 new positions and closed 7 in Q1 2025.
  • DAFNA Capital Management's portfolio value fell 10% quarter-over-quarter to $353M.

Based on DAFNA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.